Skip to main content

Peer Review reports

From: Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases

Original Submission
24 Dec 2021 Submitted Original manuscript
8 Jan 2022 Reviewed Reviewer Report
11 Jan 2022 Reviewed Reviewer Report - Jilong Yang
3 Mar 2022 Author responded Author comments - Mei-Mei Zheng
Resubmission - Version 2
3 Mar 2022 Submitted Manuscript version 2
5 Mar 2022 Reviewed Reviewer Report - Jilong Yang
16 Mar 2022 Reviewed Reviewer Report
3 Apr 2022 Author responded Author comments - Mei-Mei Zheng
Resubmission - Version 3
3 Apr 2022 Submitted Manuscript version 3
5 Apr 2022 Author responded Author comments - Mei-Mei Zheng
Resubmission - Version 4
5 Apr 2022 Submitted Manuscript version 4
Publishing
26 Apr 2022 Editorially accepted
30 May 2022 Article published 10.1186/s12916-022-02387-0

You can find further information about peer review here.

Back to article page